7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Stolina M et al. | Regulatory effects of osteoprotegerin on cellular and humoral immune responses. | 2003 | Clin. Immunol. | pmid:14697750 |
Kapczuk K et al. | [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. | 2003 | Ginekol. Pol. | pmid:12916277 |
Liu JZ et al. | [Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. | 2003 | Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi | pmid:12916296 |
Bendre MS et al. | Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. | 2003 | Bone | pmid:12919697 |
Tabb MM et al. | Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. | 2003 | J. Biol. Chem. | pmid:12920130 |
Miyahira Y et al. | Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. | 2003 | J. Immunol. | pmid:14662831 |
Seidlova-Wuttke D et al. | Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. | 2003 | Eur. J. Endocrinol. | pmid:14514351 |
Flick LM et al. | Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. | 2003 | J. Orthop. Res. | pmid:12798068 |
Khapli SM et al. | IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. | 2003 | J. Immunol. | pmid:12816992 |
Kawase Y et al. | Bone malformations in interleukin-18 transgenic mice. | 2003 | J. Bone Miner. Res. | pmid:12817749 |
Bell NH | RANK ligand and the regulation of skeletal remodeling. | 2003 | J. Clin. Invest. | pmid:12697730 |
Eghbali-Fatourechi G et al. | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. | 2003 | J. Clin. Invest. | pmid:12697741 |
Enomoto H et al. | Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. | 2003 | J. Biol. Chem. | pmid:12697767 |
Nakashima T et al. | RANKL and RANK as novel therapeutic targets for arthritis. | 2003 | Curr Opin Rheumatol | pmid:12707582 |
Liu JZ et al. | [The OPG/RANKL/RANK system and bone resorptive disease]. | 2003 | Sheng Wu Gong Cheng Xue Bao | pmid:15971575 |
Xing L et al. | Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. | 2003 | J. Bone Miner. Res. | pmid:12568403 |
Cao J et al. | Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. | 2003 | J. Bone Miner. Res. | pmid:12568404 |
Johnson-Pais TL et al. | Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. | 2003 | J. Bone Miner. Res. | pmid:12568416 |
Clohisy JC et al. | RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. | 2003 | J. Orthop. Res. | pmid:12568950 |
Walsh MC and Choi Y | Biology of the TRANCE axis. | 2003 Jun-Aug | Cytokine Growth Factor Rev. | pmid:12787563 |
Smith BB et al. | A toxicity profile of osteoprotegerin in the cynomolgus monkey. | 2003 Sep-Oct | Int. J. Toxicol. | pmid:14555415 |
Findlay DM et al. | The proliferation and phenotypic expression of human osteoblasts on tantalum metal. | 2004 | Biomaterials | pmid:14741587 |
Theoleyre S et al. | Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. | 2004 | Biochim. Biophys. Acta | pmid:14741739 |
Redlich K et al. | Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. | 2004 | Am. J. Pathol. | pmid:14742260 |
Mogi M et al. | Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. | 2004 | J. Dent. Res. | pmid:14742657 |
Heim M et al. | The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. | 2004 | Endocrinology | pmid:14605006 |
Crotti TN et al. | Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. | 2004 | Biomaterials | pmid:14607494 |
Vegni FE et al. | Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. | 2004 | N. Engl. J. Med. | pmid:14711922 |
Crisafulli A et al. | Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. | 2004 | J. Clin. Endocrinol. Metab. | pmid:14715848 |
Kubota A et al. | Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. | 2004 | J. Rheumatol. | pmid:14994384 |
Kötter I and Stübiger N | Therapeutic implications for interferon-alpha in arthritis. | 2004 | J. Rheumatol. | pmid:14994421 |
Schett G et al. | Soluble RANKL and risk of nontraumatic fracture. | 2004 | JAMA | pmid:14996780 |
Tsuji K et al. | Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2. | 2004 | J. Bone Miner. Metab. | pmid:14999519 |
Lowe CE et al. | Cost-effective analysis of candidate genes using htSNPs: a staged approach. | 2004 | Genes Immun. | pmid:15029236 |
Brown JM et al. | Opg, RANKl, and RANK in cancer metastasis: expression and regulation. | 2004 | Cancer Treat. Res. | pmid:15043192 |
Tay JY et al. | Identification of RANKL in osteolytic lesions of the facial skeleton. | 2004 | J. Dent. Res. | pmid:15044512 |
Doran PM et al. | Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. | 2004 | Exp. Hematol. | pmid:15050745 |
Kostenuik PJ et al. | Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. | 2004 | Bone | pmid:15050896 |
Baek KH et al. | Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism. | 2004 | J. Clin. Endocrinol. Metab. | pmid:15001618 |
Brage M et al. | Osteoclastogenesis is decreased by cysteine proteinase inhibitors. | 2004 | Bone | pmid:15003789 |
Fukunaga J et al. | Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. | 2004 | Bone | pmid:15003790 |
Sattler AM et al. | Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. | 2004 | Calcif. Tissue Int. | pmid:14523602 |
Skoumal M et al. | Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. | 2004 | Ann. Rheum. Dis. | pmid:14722219 |
WÅ‚odarski KH et al. | Influence of osteoprotegerin (OPG) on experimentally induced ectopic bone. | 2004 | Folia Biol. (Krakow) | pmid:19058561 |
Saidenberg-Kermanac'h N et al. | Role for osteoprotegerin in rheumatoid inflammation. | 2004 | Joint Bone Spine | pmid:14769514 |
Abu-Amer Y et al. | TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. | 2004 | J. Cell. Biochem. | pmid:15389885 |
Yang KC et al. | [Effect of nylestriol and levonorgestrel on the expression of Opg/OPGL in human osteosarcoma MG-63 cell lines]. | 2004 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | pmid:16114553 |
Roux S and Mariette X | The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. | 2004 | Leuk. Lymphoma | pmid:15359989 |
Wittrant Y et al. | RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. | 2004 | Biochim. Biophys. Acta | pmid:15363860 |
Wada N et al. | Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. | 2004 | Bone | pmid:15336598 |
Amato G et al. | High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. | 2004 | Bone | pmid:15336617 |
Ono Y et al. | Suppressive effect of Kanzo-bushi-to, a Kampo medicine, on collagen-induced arthritis. | 2004 | Biol. Pharm. Bull. | pmid:15340228 |
Farach-Carson MC et al. | Integrating rapid responses to 1,25-dihydroxyvitamin D3 with transcriptional changes in osteoblasts: Ca2+ regulated pathways to the nucleus. | 2004 | Steroids | pmid:15288767 |
Vanderborght A et al. | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. | 2004 | J. Rheumatol. | pmid:15290725 |
Soufi M et al. | Osteoprotegerin gene polymorphisms in men with coronary artery disease. | 2004 | J. Clin. Endocrinol. Metab. | pmid:15292302 |
Schoppet M et al. | Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. | 2004 | J. Clin. Endocrinol. Metab. | pmid:15292354 |
Lossdörfer S et al. | Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. | 2004 | J Biomed Mater Res A | pmid:15293309 |
Kondo T et al. | 1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. | 2004 | J. Bone Miner. Res. | pmid:15312241 |
Daroszewska A et al. | Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. | 2004 | J. Bone Miner. Res. | pmid:15312251 |
Kiefer JA et al. | The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. | 2004 | Clin. Exp. Metastasis | pmid:15672862 |
Kostenuik PJ | Revisiting the seed and soil theory of bone metastasis: new tools, same answer. | 2004 | J Musculoskelet Neuronal Interact | pmid:15758267 |
Miyashita T et al. | Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. | 2004 | Clin. Exp. Immunol. | pmid:15270863 |
Nociti FH et al. | Cementoblast gene expression is regulated by Porphyromonas gingivalis lipopolysaccharide partially via toll-like receptor-4/MD-2. | 2004 | J. Dent. Res. | pmid:15271967 |
Hashimoto T et al. | [Biochemical markers in bone metastasis]. | 2004 | Gan To Kagaku Ryoho | pmid:15272580 |
Oh KW et al. | The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. | 2004 | Clin. Endocrinol. (Oxf) | pmid:15272921 |
Doi S et al. | Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. | 2004 | Ther Apher Dial | pmid:15274686 |
Stilgren LS et al. | Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. | 2004 | Bone | pmid:15207766 |
Tsangari H et al. | Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. | 2004 | Bone | pmid:15207775 |
Garlet GP et al. | Matrix metalloproteinases, their physiological inhibitors and osteoclast factors are differentially regulated by the cytokine profile in human periodontal disease. | 2004 | J. Clin. Periodontol. | pmid:15257746 |
Baumann B et al. | Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. | 2004 | Acta Orthop Scand | pmid:15260421 |
Tomek S et al. | Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. | 2004 | Gynecol. Oncol. | pmid:15262127 |
Bord S et al. | Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. | 2004 | Br. J. Haematol. | pmid:15238146 |
Essalihi R et al. | Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a role for endothelin? | 2004 | J. Cardiovasc. Pharmacol. | pmid:15838266 |
Hofbauer LC et al. | Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. | 2004 | Acta Neuropathol. | pmid:15106011 |
Suzuki T et al. | Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL). | 2004 | J. Bone Miner. Metab. | pmid:15108059 |
Gonzalez-Calvin JL et al. | Bone mineral density and serum levels of estradiol and osteoprotegerin in postmenopausal women with viral cirrhosis. | 2004 | Gastroenterology | pmid:15057779 |
Cheng Q et al. | [Effect of osteoprotegerin gene polymorphism on bone mass in postmenopausal women]. | 2004 | Zhonghua Yi Xue Za Zhi | pmid:15059506 |
Jang HD et al. | PIAS3 suppresses NF-kappaB-mediated transcription by interacting with the p65/RelA subunit. | 2004 | J. Biol. Chem. | pmid:15140884 |
Granet C et al. | Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. | 2004 | Arthritis Res. Ther. | pmid:15142264 |
Bengtsson AK et al. | 17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. | 2004 | Blood | pmid:15142882 |
Golledge J et al. | Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. | 2004 | Stroke | pmid:15143295 |
Seshasayee D et al. | A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. | 2004 | J. Biol. Chem. | pmid:15145935 |
Yeung RS | The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. | 2004 | J. Rheumatol. | pmid:15124240 |
Masi L et al. | Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? | 2004 | J. Rheumatol. | pmid:15124262 |
Chondrogianni N et al. | Cloning of differentially expressed genes in skin fibroblasts from centenarians. | 2004 | Biogerontology | pmid:15609104 |
Martinetti A et al. | Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. | 2004 | Endocr. Relat. Cancer | pmid:15613451 |
Whyte MP and Mumm S | Heritable disorders of the RANKL/OPG/RANK signaling pathway. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615493 |
Hofbauer LC et al. | The OPG/RANKL/RANK system in metabolic bone diseases. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615494 |
Ritchlin CT et al. | RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615495 |
Clohisy DR and Mantyh PW | Bone cancer pain and the role of RANKL/OPG. | 2004 | J Musculoskelet Neuronal Interact | pmid:15615497 |
Herrmann M and Herrmann W | The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. | 2004 | Clin. Chem. Lab. Med. | pmid:15576300 |
Wittrant Y et al. | Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. | 2004 | Exp. Cell Res. | pmid:14729467 |
Hruska KA et al. | Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. | 2004 | Semin. Nephrol. | pmid:14730507 |
Zwerina J et al. | Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. | 2004 | Arthritis Rheum. | pmid:14730626 |
Mallat Z and Tedgui A | Unbalanced RANKL/RANK pathway in aortic valve sclerosis. | 2004 | J. Mol. Cell. Cardiol. | pmid:14734042 |
Kaden JJ et al. | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. | 2004 | J. Mol. Cell. Cardiol. | pmid:14734048 |
Itonaga I et al. | Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. | 2004 | Bone | pmid:14751563 |
Pan B et al. | The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). | 2004 | J. Bone Miner. Res. | pmid:14753746 |
Valverde P et al. | Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. | 2004 | J. Bone Miner. Res. | pmid:14753747 |
Buzi F et al. | Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. | 2004 | Clin. Endocrinol. (Oxf) | pmid:14678293 |